Skip to content
Home
Visit our other Journals
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Diseases
Alzheimer's Disease
Dementia
Dementia with Lewy Bodies
Frontotemporal Dementia
Vascular Dementia
Mild Cognitive Impairment
View all Diseases
Topics
Diagnostics
Biology
Biomarkers
Treatment
Clinical Care
Prevention
View all Topics
Conferences
AAIC 2023
BNA 2023
AD/PD 2023
ARUK 2023
CTAD 2022
AAIC 2022
View all Conferences
Features
Podcasts
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Donanemab
0:56
Blood-based biomarkers for treatment monitoring in Alzheimer’s disease
Suzanne Schindler
• 19 Aug 2023
1:11
Potential clinical meaningfulness of donanemab data
Rebecca Edelmayer
• 18 May 2023
1:26
Topline donanemab results: most positive Phase III data to date
Rebecca Edelmayer
• 18 May 2023
2:36
Prospects for Alzheimer’s disease monitoring and treatment in 2023
Stephen Salloway
• 19 Apr 2023
3:49
Updates on anti-amyloid monoclonal antibodies for AD in Phase III trials
Philip Tipton
• 27 Apr 2023
4:01
Use of AD blood-based biomarkers for trial enrolment
Philip Tipton
• 27 Apr 2023
2:26
Why have anti-amyloid monoclonal antibodies performed differently in Phase III trials
Stephen Salloway
• 19 Apr 2023
2:48
TRAILBLAZER-ALZ 4: direct comparison of donanemab and aducanumab
Stephen Salloway
• 19 Apr 2023
4:51
Improving the next generation of anti-amyloid antibodies: prioritizing selectivity with PMN310
Johanne Kaplan
• 30 Mar 2023
5:48
Meta-analysis of the latest anti-amyloid immunotherapies: benefit vs risk
Nicolas Villain
• 6 Dec 2022
5:40
Future direction for anti-amyloid immunotherapies
Nicolas Villain
• 6 Dec 2022
1:23
Updates in pharmacological treatment of Alzheimer’s disease: lecanemab, donanemab and gantenerumab
Stephen Salloway
• 19 Aug 2022
2:24
Is amyloid lowering still a valid approach in Alzheimer’s disease?
Johannes Streffer
• 2 Aug 2022
4:52
Important developments in dementia: biomarkers & clinical trials
Philip Tipton
• 3 Apr 2022
3:10
Donanemab: breakthrough therapy designation based on TRAILBLAZER data
Stephen Salloway
• 13 Aug 2021
8:06
Aducanumab: what’s the latest?
Stephen Salloway
• 13 Aug 2021
1
2
Next